Your browser doesn't support javascript.
Durability of immune responses after boosting in Ad26.COV2.S-primed healthcare workers.
Sablerolles, Roos S G; Rietdijk, Wim J R; Goorhuis, Abraham; Postma, Douwe F; Visser, Leo G; Schmitz, Katharina S; Geers, Daryl; Bogers, Susanne; van Haren, Eva; Koopmans, Marion P G; Dalm, Virgil A S H; Kootstra, Neeltje A; Huckriede, Anke L W; Akkerman, Renate; Beukema, Martin; Lafeber, Melvin; van Baarle, Debbie; de Vries, Rory D; van der Kuy, P Hugo M; GeurtsvanKessel, Corine H.
  • Sablerolles RSG; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Rietdijk WJR; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Goorhuis A; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Postma DF; Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Visser LG; Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands.
  • Schmitz KS; Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands.
  • Geers D; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Bogers S; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • van Haren E; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Koopmans MPG; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Dalm VASH; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Kootstra NA; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Huckriede ALW; Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Akkerman R; Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands.
  • Beukema M; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Lafeber M; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • van Baarle D; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • de Vries RD; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
  • van der Kuy PHM; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • GeurtsvanKessel CH; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Clin Infect Dis ; 2022 Jun 20.
Article in English | MEDLINE | ID: covidwho-2235112
ABSTRACT
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous booster vaccination after Ad26.COV2.S priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies and T-cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid